This FAQ explains 7-OH withdrawal, rehab options, treatment questions, drug testing, Suboxone/MAT considerations, naloxone, and when medical help is needed.

New York Senate Bill S8925A would restrict the sale and delivery of high-concentration 7-OH products, while the DEA has announced Notices of Intent to temporarily schedule covered 7-OH substances and related compounds including mitragynine pseudoindoxyl, MGM-15, and MGM-16. Learn what the law would do, how drug testing works, and why accessibility matters.

The U.S. Drug Enforcement Administration announced temporary Schedule I control of highly concentrated 7-hydroxymitragynine (7-OH), mitragynine pseudoindoxyl, MGM-15, and MGM-16. This article explains what the order covers, why it was issued, how it differs from traditional botanical kratom, and what it means for addiction professionals, retailers, and consumers.

Learn what MGM-16, MGM-15, and 7-hydroxymitragynine (7-OH) are, why Florida banned them in 2026, how they differ from kratom, and what the science says.

Thinking about buying 7-OH online? Learn the risks of concentrated 7-hydroxymitragynine products, FDA warnings, withdrawal, overdose, and how they differ from kratom.

Is 7Tabz safe? The FDA issued a warning letter on these concentrated 7-OH tablets, citing opioid-like effects, addiction risk, seizures, and overdose danger.

Drug overdose deaths continue to impact communities across the United States, with West Virginia, Alaska, and the District of Columbia reporting some of the nation’s highest overdose mortality rates. This article explores the latest overdose statistics, fentanyl-related trends, overdose warning signs, prevention strategies, and treatment resources for individuals struggling with addiction or co-occurring mental health disorders.

Addiction recovery is more than stopping substance use. Learn the definition, stages, recovery capital, support systems, relapse prevention, and what sustained recovery takes.

Defines "drug-free" across three contexts: addiction recovery, workplace policy, and prevention. Explains the Drug-Free Workplace Act of 1988 and its requirements. Breaks down the drug-free vs. substance-free distinction and why it matters for recovery housing. Addresses the MAT tension — whether people on buprenorphine or methadone are considered "drug-free." Positions the answer as individualized, not ideological.

Explains that the "J-word" refers to "junkie" and why it's considered a slur in professional contexts. Centers on the 2010 Kelly & Westerhoff Harvard/MGH study showing that clinician language directly changes treatment recommendations. Covers person-first language alternatives recommended by SAMHSA, NIDA, ASAM, and the AP. Addresses when reclamation by people with lived experience is appropriate versus when it's harmful. Links to related stigma terms — "addict," "clean/dirty," "drug abuse."

Defines relapse as a process, not a single event. Walks through the Gorski/Melemis three-stage model (emotional, mental, physical). Covers the 40-60% relapse rate and compares it to chronic disease recurrence rates for diabetes, hypertension, and asthma. Practical section on what families should do when relapse happens and how to build a prevention plan. Cites NIDA, JAMA (McLellan et al.), Yale Journal of Biology and Medicine.

Traces the campaign from Nancy Reagan's 1982 Oakland school visit through the creation of 5,000+ Just Say No clubs. Breaks down four reasons it failed: oversimplification, no evidence base, stigma/criminalization, and ignoring harm reduction. Covers D.A.R.E.'s similar failure. Closes with what evidence-based prevention looks like today — trauma-informed, community-level, social-emotional approaches.

Covers what abstinence means across clinical, legal, and cultural contexts. Explores why professionals disagree on the definition — particularly around medication-assisted treatment. Compares abstinence-based treatment, harm reduction, and MAT. Includes neuroscience of abstinence, historical/anthropological context, and practical guidance for families. Cites NIDA, SAMHSA, JAMA, and peer-reviewed addiction research.

7-OH (7-hydroxymitragynine), a potent kratom alkaloid, can produce opioid-like withdrawal symptoms after regular use. Common symptoms include anxiety, insomnia, muscle aches, sweating, and cravings. Acute withdrawal typically lasts 3–7 days, though severity depends on dosage and duration of use.

Standard 5-panel drug tests miss fentanyl, buprenorphine, and most substances now driving overdose deaths. This article examines how 22-panel CLIA-waived screening supports evidence-based intervention, strengthens treatment placement decisions, and reduces barriers to care for families in New York's Hudson Valley.

Quick take: Yes—some patients do benefit from Suboxone® (buprenorphine/naloxone) for kratom / 7-hydroxymitragynine (7-OH) withdrawal and stabilization, based mainly on case reports and clinician experience—not randomized trials. Decisions should be individualized with a qualified prescriber in New York.

7-Hydroxymitragynine (7-OH) Detox in New York: What to Know About Kratom’s Active Alkaloid

Benjamin Zohar, NCACIP  •  November 8, 2025  •  Last reviewed: November 8, 2025

Quick take: 7-Hydroxymitragynine (7-OH) is a primary active alkaloid in kratom products. Heavy or prolonged use can lead to dependence and withdrawal. This New York–focused guide covers symptoms, when to consider medical detox, and how to plan safe, evidence-informed care—plus statewide resources and testing options.

What Is 7-OH & How Does It Relate to Detox?

7-OH in context: A potent kratom alkaloid associated with...